Journal of Stem Cell Research & Therapy

T-cellâ??based therapeutic modality in solid tumours

6^th International Conference and Exhibition on Cell and Gene Therapy

March 27-28, 2017 Madrid, Spain

Weidong Han

Chinese PLA General Hospital, China

Scientific Tracks Abstracts: J Stem Cell Res Ther

Abstract:

The clinical successes of CD19-targeted chimeric antigen receptor (CAR) T-cell treatment in B-cell lineage hematopoietic malignancies in recent years, especially in acute lymphocytic leukemia (ALL), have shown that tumour cells can be precisely and efficiently targeted and eliminated by tumour-associated antigen-redirected immune cells. However, consideration of the significant differences between liquid and solid tumours is needed to ascertain rational, feasible, and efficient CAR T-cellâ??based therapeutic modalities in solid tumours. How to precisely instruct transfused CAR T cells to attack tumour cells growing outside of normal circulation is still a great challenge. Herein, we would like to briefly introduce CD20-, CD30-directed CAR T trials in patients with refractory lymphomas, and will emphatically address the results from our clinical trial data in patients with relapsed/refractory solid tumours treated by autoglous EGFR-, HER2-, and CD133-directed CAR T-based therapeutic modality.

Biography :

Weidong Han, MD, PhD, is the Director of Department of Molecular Immunology/Bio-therapeutics, Director of Department of Stem Cell and Tissue Regeneration in Chinese PLA General Hospital. He is a pioneer in the field of tumor immunotherapy, who initially developed the clinical translation of chimeric antigen receptor T (CART) cells in China. He holds 10 projects of clinical trial, including 8 registered CART-based trials (CART19, CART20, CART30, CART33, CARTEGFR, CARTHER- 2, and CART-138). The patents were also applied or obtained in China. In recent 10 years. He obtained 9 grants in China and published more than 80 papers in international journals.

Email: hanwdrsw69@yahoo.com